
Kezar Life Sciences Inc (NASDAQ:KZR) shares are trading lower by 38.23% at $7.61 after the company announced top-line results from its PRESIDIO Phase 2 clinical trial of Zetomipzomib.
Kezar Life Sciences says most patients saw clinically meaningful improvements in the primary endpoint measure of Total Improvement Score (TIS), but no differentiation from placebo was observed.